4.5 Review Book Chapter

Heparin-Induced Thrombocytopenia

期刊

ANNUAL REVIEW OF MEDICINE
卷 61, 期 -, 页码 77-90

出版社

ANNUAL REVIEWS
DOI: 10.1146/annurev.med.042808.171814

关键词

platelet factor 4; heparin; thrombosis; immunoassays; direct thrombin inhibitors; immune thrombocytopenia; immune-mediated thrombosis

资金

  1. GlaxoSmithKline
  2. Momenta Pharmaceuticals
  3. Centers for Disease Control and Prevention [U01DD000014]
  4. National Institutes of Health [HL081395, U54HL077878, U01HL087229, U01HL072289]
  5. CENTERS FOR DISEASE CONTROL AND PREVENTION [U01DD000014] Funding Source: NIH RePORTER
  6. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL077878, R01HL081395, U01HL087229, U01HL072289] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytopenia or thrombocytopenia complicated by thrombosis. The propensity for thrombosis distinguishes HIT from other common drug-induced thrombocytopenias. Diagnosing HIT in hospitalized patients is often challenging because of the frequency of heparin use, occurrence of thrombocytopenia from other causes, and development of asymptomatic PF4/heparin antibodies in patients treated with heparin. This review summarizes our current understanding of the pathogenesis, clinical features, diagnostic criteria, and management approaches in HIT

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据